anti-CD19-CD3E-CAR-T cells

Anti-CD19-CD3E-CAR-T cells are a form of chimeric antigen receptor T cell (CAR-T) therapy in which autologous T lymphocytes are genetically engineered to express a synthetic receptor targeting the CD19 antigen, commonly found on B-cells. The construct also incorporates signaling domains from CD3 epsilon (CD3E), enhancing T cell activation upon antigen engagement. These modified T cells recognize and bind to CD19-expressing target cells, leading to their destruction through cytolytic activity and cytokine release. Anti-CD19 CAR-T therapies have shown high efficacy in inducing remission in relapsed or refractory B-cell malignancies such as acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][4][8]. More recently, they are being investigated for use in relapsed or refractory autoimmune diseases[2]. The therapy typically involves collection of patient’s own T-cells, ex vivo genetic modification using viral vectors (such as lentivirus or gammaretrovirus), expansion, and reinfusion following lymphodepleting chemotherapy[1][2].

Other names

anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCD19-targeted CAR T cellsCD-19-targeted CAR T cellsCD 19-targeted CAR T cells